RIPK1 and early-onset autosomal dominant Alzheimer disease: Currently, several RIPK1 inhibitors, GSK′2982772, DNL747, and DNL758, are in phase 1 or 2 clinical trials targeting inflammatory diseases such as psoriasis, ulcerative colitis, severe rheumatoid arthritis, Alzheimer’s disease, amyotrophic lateral sclerosis, and COVID-1995,96.